87. Casu C, Presti VL, Oikonomidou PR, et al. Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of beta-thalassemia intermedia and major. Haematologica 2018; **103**: e46-e9.
88. Taher AT, Karakas Z, Cassinerio E, et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood 2018; **131**: 263-5.
89. Matte A, Federti E, Winter M, et al. Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia. JCI Insight 2019; **4**: e130111.
90. Taher AT, Viprakasit V, Cappellini MD, et al. Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent beta-thalassaemia. Br J Haematol 2021; **194**: 474-7.
91. Casu C, Oikonomidou PR, Chen H, et al. Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood 2016; **128**: 265-76.
92. Casu C, Chessa R, Liu A, et al. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major. Haematologica 2020; **105**: 1835.
93. Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD. Beta thalassemia: new therapeutic options beyond transfusion and iron chelation. Drugs 2020; **80**: 1053-63.
94. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest 2013; **123**: 1531-41.
95. Schmidt PJ, Toudjarska I, Sendamarai AK, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 2013; **121**: 1200-8.
96. Porter J, Taher A, Viprakasit V, et al. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in beta-thalassemia: current evidence and future clinical development. Expert Rev Hematol 2021; **14**: 633-44.
97. Manolova V, Nyffenegger N, Flace A, et al. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of beta-thalassemia. J Clin Invest 2019; **130**: 491-506.
98. Nyffenegger N, Flace A, Doucerain C, et al. The oral ferroportin inhibitor VIT-2763 improves erythropoiesis without interfering with iron chelation therapy in a mouse model of beta-thalassemia. Int J Mol Sci 2021; **22**: 873.
99. Richard F, van Lier JJ, Roubert B, et al. Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers. Am J Hematol 2020; **95**: 68-77.
100. Baronciani D, Casale M, De Franceschi L, et al. Selecting beta-thalassemia patients for gene therapy: a decision-making algorithm. Hemasphere 2021; **5**: e555.
101. Leibowitz ML, Papathanasiou S, Doerfler PA, et al. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat Genet 2021; **53**: 895-905.